Bruce Montgomery, M.D. | CEO
Dr. Montgomery has more than 25 years of drug development, operations and financing experience, including positions at Genentech, Pathogenesis, Corus Pharma, and Gilead Sciences. He led development of the only 3 currently marketed antimicrobials for inhalation, (aerosolized pentamidine, Tobramycin Inhalation Solution [TOBI®], and Aztreonam Inhalation Solution [Cayston®]) and initiated multiple other programs that have resulted in drug approvals, including Pulmozyme®, Xolair® and Raptiva®. Dr. Montgomery has raised over 200 million dollars in venture and public financings.
Prior to founding Cardeas, Dr. Montgomery served 4 years as Senior Vice President of Gilead Sciences, and 6 years as Chief Executive Officer of Corus Pharma, a specialized biotechnology company focusing on infectious disease and respiratory drugs that he founded, and which was acquired by Gilead in 2006. Dr. Montgomery also served as Executive Vice President of Research and Development at PathoGenesis Corporation until its acquisition by Chiron in 2000.
In 1998 the FDA Commissioner recognized Dr. Montgomery with a special citation for leadership in the development and approval of TOBI. For this work, Dr. Montgomery also received the 2009 Inventor of the Year award from the University of Washington. In 2010, Dr. Montgomery received a scientific achievement award from the Cystic Fibrosis Foundation for his work on Pulmozyme, TOBI, and Cayston, which collectively have extended the average life span of cystic fibrosis patients by over a decade. In 2011, he received a career achievement award from the International Society for Aerosols in Medicine.
Dr. Montgomery received his B.S. in Chemistry (Magna cum Laude, Outstanding Chemistry Major [Merck Award]), and M.D. (Alpha Omega Alpha Honor Medical Society) from the University of Washington, Seattle. Dr. Montgomery is a board certified internist and pulmonologist. He has served as a board member for ZymoGenetics, and is currently on the board of Alder Pharmaceuticals. In 2012, Dr. Montgomery was honored as one of the top 150 living graduates of the University of Washington College of Arts and Sciences in conjunction with the 150th anniversary of the university.
Melissa Yeager, J.D. | COO
Ms. Yeager has over 20 years of management responsibility for regulatory and marketing activities in the pharmaceutical, medical device, and biotechnology fields. She has worked with Dr. Montgomery for 15 years; together they led development of Tobramycin Inhalation Solution (TOBI®) and Aztreonam Inhalation Solution (Cayston®). Ms. Yeager played an instrumental role in gaining approval for Cayston after both the EMA and FDA rejected the initial applications.
Ms. Yeager’s broad experience in product development includes management positions with Gilead Sciences, Becton Dickinson and other Fortune 500 corporations, as well as smaller, specialized biotechnology ventures including Corus Pharma and PathoGenesis. In these roles, she has provided key leadership through all phases of drug, device and combination product development both in the US and overseas. Ms. Yeager’s major achievements include drug, device and combination product approvals (including orphan products), primarily related to infectious, respiratory and cardiovascular diseases, in more than 40 countries.
Prior to joining Cardeas, Ms. Yeager served nine years as Vice President of Regulatory Affairs at Corus Pharma and Gilead Sciences, guiding regulatory and quality assurance activities for multiple products. Her key responsibilities in this role included guiding preclinical, clinical and CMC regulatory strategies, managing pre- and post-approval regulatory activities for compliance with FDA and world health agency standards, and ensuring compliance with good clinical, laboratory and manufacturing processes and practices worldwide. She also led development of novel systems to track and assess research, development and clinical compliance, directed eCTD implementation, and established publication standards.
Ms. Yeager received her B.A. degree in Human Biology from Stanford University and her J.D. degree from Santa Clara University. She is currently a member of leadership boards of nonprofit organizations.
Board of Directors
Aaron Davidson is a Managing Director of H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector. Mr. Davidson began his career with Eli Lilly Company, where he spent a decade in various management roles in the United States and Canada including business development, strategic planning, market research and financial planning. Mr. Davidson currently serves on the boards of Alder Biopharmaceuticals, Inc., HyperBranch Medical Technology, Intact Vascular, NeurAxon Inc., and Novadaq Technologies. He served on the boards of Salmedix and Gemin X Pharmaceuticals prior to their acquisitions by Cephalon in 2005 and 2011 respectively and the board of Oncogenex Pharmaceuticals prior to their public listing. Mr. Davidson earned his MBA from Harvard Business School and a Bachelor of Commerce degree from McGill University.
Robert deGavre previously served as Senior Vice President and Chief Financial Officer of Westmark International, a company formed as a spin-off by Squibb Corporation. Westmark developed and marketed diagnostic ultrasound equipment through its subsidiary ATL and patient monitoring equipment through SpaceLabs Medical. Mr. deGavre also served as Vice President and Treasurer of Squibb Corporation and as Treasurer of Inco Limited. He has also served as the Chairman of the Advisory Committee to Princeton’s Economics Department. Mr. deGavre graduated Phi Beta Kappa from Woodrow Wilson School at Princeton University and after serving four years as an officer in the U.S. Navy’s submarine service, returned to the University to earn an M.P.A. In addition, he served on the Board of Directors of Corus Pharma from 2001 until its acquisition by Gilead Sciences in 2006.
Kevin Kinsella founded Avalon Ventures in 1983. He has specialized in the formation, financing and development of more than 100 early-stage companies. Prior to founding Avalon, Mr. Kinsella served in senior management positions at Solar Turbines International (Caterpillar Tractor) where he was in charge of all international joint ventures, barter and counter-trade. Mr. Kinsella is a graduate of the Massachusetts Institute of Technology (MIT) with a Bachelor of Science degree in management, and minors in electrical engineering and political science. He holds a Master of Arts degree in international relations from the Johns Hopkins School of Advanced International Studies (SAIS). He studied political economy at the University of Stockholm on a Rotary International Fellowship. Kinsella won the 2006 Tony Award for producing the Broadway mega-hit musical, Jersey Boys and won a second Tony nomination for producing Jesus Christ Superstar. His winery, Kinsella Estates, has the highest rated Cabernet in the Dry Creek Valley, achieving a 95 point rating from Wine Spectator and 94 points from The Wine Advocate and was named one of the top five small Cabernet producers in California by Wine Spectator. Mr. Kinsella serves on the Council on Foreign Relations and is a voting member of the Broadway League. Mr. Kinsella is on the Board of Directors of Avelas Biosciences and Juliet Marine Systems.
Peter Moldt joined Novo A/S in 2009. He is a member of the Board of Directors of Orphazyme ApS, and was a board member of Cytochroma Inc., HemoFocus ApS and Neurokey A/S. In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000 – 2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. Peter holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy. He also held a post-doctoral position with Yale University’s department of organic chemistry.
Mr. Scullion is a global healthcare industry leader with over 35 years of senior operational and strategic biopharmaceutical experience in the U.S., Europe, Japan and Asia. In addition to his experience in Global Marketing and Country/Regional P+L line roles, his significant breadth of responsibilities includes past positions as Senior Vice President of New and International Business Development at Pfizer Inc.; Chairman and CEO of Memory Pharmaceuticals Inc., taking the company public before its acquisition by Roche and Head of Global Business Development at GlaxoWellcome plc (now GSK) and a member of its Management Committee. In addition, he has served as Chairman of Trellis Bioscience Inc. and as a member of the Board of Directors of EKR Therapeutics, Dynogen Pharmaceuticals and the Biotechnology Council of New Jersey. Mr. Scullion has a Bachelor’s degree in Physiology and a Master’s degree in Pharmacology both from the University of London.
Mr. Caracciolo has over 30 years of experience in the pharmaceutical sciences. During 14 years at Gilead Sciences, he served as Senior Vice President of Manufacturing, directing the operations of two manufacturing locations and a worldwide portfolio of contract manufacturing organizations, as well as information technology and corporate engineering. Prior to Gilead, he was Vice President of Operations for Bausch and Lomb’s pharmaceutical division. Before joining Bausch and Lomb, he held various management positions at Sterling Drug for over 13 years. Mr. Caracciolo serves on the Board of Directors of CytoDyn Pharmaceuticals in Tampa, Florida. Mr. Caracciolo has a Bachelor of Science degree in Pharmacy from St. John’s University.
Dr. Feigal is a principal in NDA Partners LLC and an Adjunct Professor at the O’Connor School of Law at Arizona State University where he teaches food and drug law and policy. After receiving his M.D. from Stanford University, and training in internal medicine, Dr. Feigal was a member of the full time faculty in the schools of medicine at the University of California at San Francisco and San Diego. He later spent twelve years at the FDA as Director of the Antiviral Drug Division, the Anti-Infective Drug Division and ODE IV in the Center for Drug Evaluation and Research, the Medical Deputy Director in the Center for Biologics Research and Evaluation, and as the Director of the Center for Devices and Radiological Health. After leaving the FDA, Dr. Feigal served as Vice President for Global Regulatory Affairs at Amgen, and Senior Vice President for Global Regulatory and Safety at Élan Pharmaceuticals. He has served on the Board of Directors of Renovo Ltd. and Aspect Medical Inc., as well as an advisory board member for many other companies.
Dr. Mann is a board-certified pulmonologist and an independent consultant specializing in development of drugs for pulmonary diseases. She worked at the FDA for 9 years, starting in 1994 as a primary medical officer in the Division of Antiviral Drug Products and Division Special Pathogens and Immunologic Drug Products. She became Deputy Director of the Division of Reproductive and Urologic Drug Products in 1997. In 2000, she joined the Division of Pulmonary and Allergy Drug Products as Deputy Director where she served until her departure from the FDA in 2003. Following her tenure at the FDA, Dr. Mann was Branch Chief at the NIH (NIAID). Dr. Mann has been an active consultant and advisory board member of FDA-regulated companies since she left government work in 2004.